LBRX
LB Pharmaceuticals Inc Common StockHealthcare·Biotechnology
$27.97
$802M market cap
Revenue
$0.0M
Free Cash Flow
$-41.5M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Clinicalâstage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LBâ102, a methylated derivative of amisulpride.
2-Year Price History
$28.12+67.4%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -22.0 | -22.1 | -19.1 | -23.3 | -23.3 | -0.0 | 365.6 | 3.5 | 28.2 | -49.9% | -- | -- |
| Act | 2025-Q4 | 0.0 | -13.8 | -13.9 | -11.5 | -18.1 | -18.1 | -0.0 | 295.2 | 3.6 | 25.3 | -54.7% | -- | -- |
Valuation & Metrics
Market Stats
Price$27.97
Market Cap$802M
Enterprise Value$440M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-5.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-30.5M
Free Cash Flow$-41.5M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-52.3%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares3.8M
Days to Cover14.8
Change (vs Prior)+22.2%
Need at least 2 settlement dates for chart
Employees
Headcount16
Revenue / Employee$0
Gross Profit / Employee$-5,125
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
71.7%(+34.3% YoY)
68 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
14.9%(+12.9% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.0%(-0.1% YoY)
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Deep Track Capital, LP | $82.7M | $15.79 | +$0 | +$82.7M | -1.2% | $4.85B |
| BlackRock, Inc.Passive | $60.9M | $19.93 | +$5.7M | +$60.9M | -0.2% | $5.69T |
| RA CAPITAL MANAGEMENT, L.P. | $54.5M | $17.05 | +$0 | +$54.5M | -4.4% | $9.44B |
| TCG Crossover Management, LLC | $45.3M | $16.25 | +$2.3M | +$45.3M | +4.6% | $3.50B |
| Commodore Capital LP | $37.0M | $15.79 | +$0 | +$37.0M | -0.1% | $1.73B |
| Caligan Partners LP | $34.6M | $24.66 | +$35.5M | +$34.6M | +6.8% | $1.41B |
| Spruce Street Capital LP | $33.6M | $22.91 | +$9.1M | +$33.6M | +58.0% | $416M |
| JPMORGAN CHASE & CO | $33.2M | $18.11 | −$4.5M | +$33.2M | -0.2% | $1.47T |
| Trails Edge Capital Partners, LP | $32.5M | $22.26 | −$1.9M | +$32.5M | +12.0% | $425M |
| Nantahala Capital Management, LLC | $26.0M | $18.97 | +$9.3M | +$26.0M | -2.4% | $1.60B |
| BALYASNY ASSET MANAGEMENT LLC | $22.8M | $16.03 | +$663K | +$22.8M | -0.4% | $48.01B |
| Logos Global Management LP | $22.6M | $16.17 | −$7.0M | +$22.6M | -1.6% | $1.94B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $22.1M | $24.66 | +$22.1M | +$22.1M | — | $4.04T |
| Alyeska Investment Group, L.P. | $21.3M | $17.73 | +$4.7M | +$21.3M | -0.5% | $35.33B |
| Vivo Capital, LLC | $19.7M | $15.79 | +$0 | +$19.7M | -7.0% | $1.20B |
| Nan Fung Group Holdings Ltd | $15.6M | $20.44 | +$8.2M | +$15.6M | -4.3% | $120M |
| JENNISON ASSOCIATES LLC | $13.3M | $16.44 | −$7.0M | +$13.3M | +2.7% | $145.31B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $12.8M | $22.45 | +$1.9M | +$12.8M | +2.3% | $1.61T |
| STATE STREET CORPPassive | $12.4M | $23.47 | +$6.3M | +$12.4M | -0.2% | $2.89T |
| CITADEL ADVISORS LLC | $10.3M | $15.94 | +$228K | +$10.3M | -0.4% | $138.22B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+3.52%
avg per quarter
Holders (ex-self)
+3.75%
excl. this stock
Buyers (this Q)
+7.17%
49 buyers · $0.16B in
Sellers (this Q)
-0.68%
16 sellers · $0.02B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
+1.4%
how holders react when this stock falls
On quiet Qs
+0.1%
−10% to +10% baseline
On rallies (+10%+)
+0.6%
how they react when this stock rises
Holders' portfolio flow this Q
+1.1%
inflows — adds are organic
Sellers' portfolio flow this Q
-0.3%
Sellers' overall flow ~ flat.
Biggest decreases this quarter
Logos Global Management LP−$7.0Mα-1.6JENNISON ASSOCIATES LLC−$7.0Mα+2.7JPMORGAN CHASE & CO−$4.5Mα-0.2Trails Edge Capital Partners, LP−$1.9Mα+12.0Longbow Finance SAexited−$1.8MJANE STREET GROUP, LLCexited−$706KXTX Topco Ltdexited−$426KMARSHALL WACE, LLPexited−$401KJefferies Financial Group Inc.exited−$277KSG Americas Securities, LLCexited−$143K
New buyers this quarter
Top-5 holders · 40.5%
Deep Track Capital, LP--
BlackRock, Inc.--
RA CAPITAL MANAGEMENT, L.P.--
TCG Crossover Management, LLC--
Commodore Capital LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Deep Track Capital, LP3.4MRA CAPITAL MANAGEMENT, L.P.2.2MTCG Crossover Management, LLC1.8MCommodore Capital LP1.5MJPMORGAN CHASE & CO1.4MCaligan Partners LP1.4MSpruce Street Capital LP1.4MTrails Edge Capital Partners, LP1.3MLogos Global Management LP915KNantahala Capital Management, LLC1.1M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| SVRA | Savara Inc. | 3 | 238.95× |
| TYRA | Tyra Biosciences, Inc. | 4 | 227.57× |
| SYRE | Spyre Therapeutics, Inc. | 4 | 187.41× |
| IMVT | Immunovant, Inc. | 3 | 183.81× |
| RLAY | Relay Therapeutics, Inc. | 3 | 170.68× |
| TNGX | Tango Therapeutics, Inc. | 3 | 159.30× |
| AMLX | Amylyx Pharmaceuticals, Inc. | 3 | 149.34× |
| PCVX | Vaxcyte, Inc. | 4 | 132.75× |
| XENE | Xenon Pharmaceuticals Inc. | 3 | 113.79× |
| RVMD | Revolution Medicines, Inc. | 5 | 73.75× |
| COGT | Cogent Biosciences, Inc. | 3 | 72.41× |
| ABVX | Abivax S.A. | 3 | 58.28× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (4 analysts)$39.504120.0%
Last Year (8 analysts)$35.632740.0%
Current Price$27.97
Analyst Ratings
1
Buy: 1Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
10.7%retail-1.7pp
33.8%dark+6.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.